
EndoDrill is recognized as a promising new product for solving a significant clinical problem in a medical journal

The cancer diagnostics company BiBBInstruments AB ("BiBB"), the developer of EndoDrill®, the world's first market-cleared motorized endoscopic core biopsy instrument, informs that EndoDrill® is recognized as a promising new EUS product on the editorial page of the South American medical journal *Revista de Gastroenterología del Perú*.

"It is encouraging that EndoDrill is recognized as a promising new EUS instrument in an editorial that describes the future of endoscopic ultrasound. In addition, by an endoscopist who has recently tested the product clinically", says Dr Charles Walther, CMO and Founder of BiBB.

In a recent editorial in the journal *Revista de Gastroenterología del Perú*, *Echoendoscopy: past, present and future of a trip to inner space* (Volume 44, No 1, 2024), Dr. Mendoza Ladd, Medical Director of Endoscopy at UC Davis Health in Sacramento, CA, describes the rapid development of endoscopic ultrasound (EUS) procedures. In just a few decades, EUS has become a fundamental tool for various gastrointestinal disorders, e.g. pancreatic tumors. Editorial writer Dr. Mendoza Ladd mentions, among other things, that we are now seeing an explosion in the diagnostic and therapeutic use of EUS.

As communicated earlier Dr. Mendoza Ladd is evaluating EndoDrill® GI at UC Davis Health, as a new biopsy instrument that could significantly improve the diagnostic yield. In this editorial he explicitly mentions EndoDrill® as a promising candidate that could finally solve the problem of insufficient tissue samples sent to the pathology lab. Dr. Mendoza Ladd concludes that without enough tissue, there is no clear diagnosis: tissue is the issue.

The journal, in Spanish, is available here:

<https://revistagastroperu.com/index.php/rgp/article/view/1675/1227>

About EndoDrill® GI

EndoDrill® GI is the world's first market-cleared electric-driven biopsy instrument for endoscopic ultrasound (EUS). The instrument is used for EUS-guided tissue sampling for all indications in the gastrointestinal tract, e.g. pancreas, stomach, esophagus, lymph nodes, and liver. EndoDrill® GI received FDA 510(k) clearance in the US in 2023 and CE approval in Europe in early 2024. The product is being evaluated clinically in the US and Scandinavia with a planned launch in Sweden later in 2024.

This is a translation of the Swedish press release. If there should be any discrepancies, the Swedish language version prevails.

BiBBInstruments AB
Press release, June 04, 2024



Medicon Village
SE-223 81 Lund
www.bibbinstruments.com

For more information about BiBB, please contact:

Fredrik Lindblad, CEO

E-mail: fredrik.lindblad@bibbinstruments.com

Phone: +46 70 899 94 86

www.bibbinstruments.com

About BiBB

The cancer diagnostics company BiBBInstruments AB develops and manufactures EndoDrill®, a patented product series of electric-driven endoscopic biopsy instruments. The EndoDrill® instruments take high-quality tissue samples with high precision with the goal of improving the diagnosis of several serious cancers, e.g., in the stomach, pancreas, liver, lung, and bladder. The product portfolio targets the global market for endoscopic ultrasound guided (EUS/EBUS) biopsy instruments, which is the most advanced and fast-growing area of endoscopy. In 2023, EndoDrill® GI, BiBB's most important product variant, received market clearance from the US FDA as the first electric biopsy instrument for endoscopy in the US. The EndoDrill® system includes sterile disposable needle biopsy instruments with associated drive system (reusable part). The company was founded in 2013 by Dr Charles Walther, cancer researcher at Lund University and chief physician in clinical pathology at Skåne University Hospital in Lund. BiBBInstruments is based at Medicon Village in Lund and BiBBInstrument's share (Ticker: BIBB) is listed on Spotlight Stock Market.